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It has been previously shown that the polycomb
protein BMI1 and E4F1 interact physically and
genetically in the hematopoietic system. Here, we
report that E4f1 is essential for hematopoietic cell
function and survival. E4f1 deletion induces acute
bone marrow failure characterized by apoptosis of
progenitors while stem cells are preserved. E4f1-
deficient cells accumulate DNA damage and show
defects in progression through S phase and mitosis,
revealing a role for E4F1 in cell-cycle progression
and genome integrity. Importantly, we showed that
E4F1 interacts with and protects the checkpoint
kinase 1 (CHK1) protein from degradation. Finally,
defects observed in E4f1-deficient cells were fully
reversed by ectopic expression of Chek1. Alto-
gether, our results classify E4F1 as a master
regulator of CHK1 activity that ensures high fidelity
of DNA replication, thus safeguarding genome
stability.INTRODUCTION
Conservation of tissue integrity relies upon a delicate balance
between cell division and differentiation. This requires a
reliable system to protect genetic information against harmful
DNA damage. Notably, dividing cells are susceptible to
genotoxic insults during DNA duplication in S phase and rely
on the ATR/CHK1 DNA damage response pathway. This is
essential to ensure proper DNA damage signaling at the
origin of DNA repair, genome stability, and cell survival (Bartek
et al., 2004; Cimprich and Cortez, 2008). This dependence is
exacerbated in cancer cells, which commonly display a210 Cell Reports 11, 210–219, April 14, 2015 ª2015 The Authorsdysfunctional G1/S phase transition, thereby augmenting repli-
cation stress during DNA synthesis (Chen et al., 2012). In this
regard, among the various G1/S gatekeepers, the Zn-finger
protein E4F1 is of particular interest, as it orchestrates the inter-
play of pro- and anti-proliferative signals mediated by potent
cell-cycle regulators such as p53, RB1, and the polycomb
member BMI1 (Fajas et al., 2000; Chagraoui et al., 2006; Le
Cam et al., 2006). However, detailed molecular studies aiming
at deciphering E4f1 function have been hampered by the
severity of E4f1 knockout phenotypes (Le Cam et al., 2004;
Lacroix et al., 2010).
In the current study, we took advantage of conditional E4f1
loss-of-function approaches to investigate the role of E4f1 in
hematopoietic cells. E4f1 deletion has a dramatic phenotype:
mice die of an acute bone marrow aplasia within 2 weeks of
E4f1-induced deletion. We show that E4f1 regulates hematopoi-
etic cell survival in a p53-independent manner. Similar to ATR/
CHK1-deficient cells (Brown and Baltimore, 2000; Liu et al.,
2000; Takai et al., 2000), we find that E4f1 mutant cells exhibit
slowed replication fork progression, acquire massive DNA dam-
age, and enter mitosis before completion of DNA replication.
Additionally, we find that E4F1 physically interacts with CHK1
and critically regulates its expression, mostly at the post-transla-
tional level. Restoration of CHK1 expression in E4f1 mutant
mouse embryonic fibroblasts (MEFs) rescues their proliferation,
suppresses the DNA damage phenotype, and restores the ATR/
CHK1 checkpoint functions. The E3 ubiquitin ligase E4F1,
initially identified as a transcription factor (Fajas et al., 2001), is
essential for cell-cycle progression and genome integrity in
actively dividing cells. Its numerous known interactors suggest
that E4F1 is a multifunctional protein. Among its functions, our
data suggest that the tight regulation of the CHK1 protein is a
major contributor to the observed E4f1 phenotype. Accordingly,
E4f1 knockout mice are embryonic lethal and phenocopy all
defects observed in theChek1-null mutant (Liu et al., 2000; Takai
et al., 2000; Le Cam et al., 2004).
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Figure 1. E4f1 Is Essential for Hematopoi-
etic Cell Maintenance
(A) qRT-PCR of E4f1 in total BM and sub-pop-
ulations of hematopoietic cells. Results were
normalized with the endogenous control Gapdh.
Experiments were repeated twice with BM cells
extracted from two series of 150 animals.
(B) Targeting strategy to generate a conditional
E4f1 loss-of-function allele (1–14, E4f1 exons; Frt,
Flpe recombinase recognition site; LoxP, Cre-re-
combinase recognition site; neo, neomycin selec-
tion cassette; probe, approximate position of
Southern blotting probe; XmaI, XmaI restriction
site).
(C) Experimental protocol for conditional E4f1
deletion in the adult hematopoietic system (top)
and Kaplan-Meyer survival curves (bottom) of
control (Mxcre E4f1+/+ and Mxcre E4f1D/+) and
mutant (Mxcre E4f1D/D) animals (n R 4 mice/
genotype).
(D) Total femur cell count in controls (Mxcre E4f1+/+
andMxcre E4f1D/+) andmutant (Mxcre E4f1D/D) mice
(means ± SD; nR 4 mice/genotype).
(E) Representative histological sections of H&E-
stained femurs (top) and Wright-Giemsa-stained
cytospin preparation (bottom) of BM cells isolated
from Mxcre E4f1D/+ (control) and Mxcre E4f1D/D
animals.
(F) In vitro colony-forming assay of BM cells iso-
lated from control and E4f1 mutant mice (CFU,
colony forming unit; G, granulocyte; GEMM,
granulocyte erythroid macrophage megakaryo-
cyte; GM, granulocyte/macrophage; M, macro-
phage; means ± SD; n = 4 mice/genotype).
See also Figure S1.RESULTS
E4f1 Is Essential for Hematopoietic Cell Function and
Survival
We previously reported a genetic interaction between E4f1
and the well-known polycomb member Bmi1 in hematopoietic
cells (Chagraoui et al., 2006). These results suggested an
important and unknown role of E4f1 in these cells. First, we
evaluated E4f1 expression in total bone marrow (BM) and
specific hematopoietic cells subsets including differentiated
populations (Lin+), progenitors (CLP [common lymphoid pro-
genitor] and CMP [common myeloid progenitor]) and stem cells
(LSK CD34+ and LSK CD34). We found that E4f1 exhibits
a consistent and homogenous expression in all these hemato-
poietic sub-populations (Figure 1A). In order to study E4f1
function in hematopoietic cell populations, we inactivated the
gene in the adult hematopoietic system using a newly gener-Cell Reports 11, 210–ated conditional knockout mouse in
combination with the Mx-cre system
(Figure 1B). This allows the inducible
expression of the Cre recombinase in he-
matopoietic cells including stem cells
(HSCs; Ku¨hn et al., 1995). Southern blot
analysis in MEFs showed efficient DNArecombination (Figure S1A), and immunoblot confirmed loss
of E4F1 expression after retroviral mediated Cre delivery
(Figure S1B).
We treated adult mice with pIpC in order to delete specifically
E4f1 floxed alleles in the hematopoietic cells. Whereas no
obvious abnormalities were observed inMxcre E4f1+/D andMxcre
E4f1+/+ mice, Mxcre E4f1D/D mice died rapidly (within 2 weeks
following pIpC first administration; Figure 1C). Necropsy of the
moribund animals revealed a pronounced BM aplasia with an
important decrease in the absolute number of total BM cells
(Figure 1D) and a rapid loss of most mature myeloid cells (Fig-
ure 1E, see loss of neutrophils in lower right panel). Consistent
with the severe aplasia, little if any progenitor activity could be
recovered from E4f1 mutant BM cells (Figure 1F). Notably, het-
erozygous deletion of E4f1 had no impact in hematopoietic cell
viability, suggesting that lowering E4F1 level is not critical for cell
survival.219, April 14, 2015 ª2015 The Authors 211
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Figure 2. E4f1 Deletion Induces a Massive Apoptosis of Progenitors whereas Stem Cells Are Preserved
(A) Percentage of donor-derived Ly5.2 cells was assessed by flow cytometry on peripheral blood cells in the non-competitive design at 4 weeks post-trans-
plantation and 4 and 6 weeks post-pIpC treatment (means ± SD; n = 2–5 mice/genotype).
(B) Reconstitution levels of donor-derived Ly5.2 cells in the mixed BM chimeras were analyzed at 6 weeks post-pIpC (means ± SD; n = 2–5 mice/genotype).
(C) Representative FACS profiles of control donor cells (Ly5.2Mxcre E4f1+/+), E4f1-deleted donor cells (Ly5.2Mxcre E4f1D/D) and normal competitors (Ly5.1) from
the same animal. BM were analyzed 6 weeks post-pIpC for their content in myeloid progenitors (MPs), Lin Sca1+ cKit+ (LSK), multipotent progenitors (MPPs),
short-term repopulating cells (ST-HSC), and long-term repopulating cells (LT-HSC) (n = 2–5 mice/genotype).
(D) Absolute cell numbers of different hematopoietic populations derived from control donor cells (Ly5.2 Mxcre E4f1+/+), E4f1-deleted donor cells (Ly5.2 Mxcre
E4f1D/D), and normal competitors (Ly5.1) were evaluated in chimeras BM (non-competitive setup) at 6 weeks post-pIpC (means ± SD; n = 2–5 mice/genotype).
(legend continued on next page)
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E4f1 Deficiency Results in Cell-Autonomous
Hematopoietic Defects
The rapid lethality of E4f1mutant primary mice (Figure 1C) along
with short-term side effects of pIpC administration (Essers et al.,
2009) precluded the analysis of the hematopoietic system as
classically performed. To overcome this issue, chimeras were
generated. Briefly, BM cells isolated from control Mxcre
E4f1+/+orMxcre E4f1F/F (Ly5.2+) mice were transplanted into sub-
lethally irradiated Ly5.1+ congenic recipients. E4f1 gene deletion
were induced in pre-established chimeras, in which donor-
derived cells (Ly5.2+) represented either 90% (non-competitive
setup) or 50% (competitive setup) of the peripheral blood (Fig-
ure S2A). In contrast to donor E4f1+/+ control cells, contribution
of E4f1D/D cells to peripheral blood rapidly declined (Figures 2A
and S2B). At 6 weeks post-pIpC treatment, less than 10% of
E4f1D/D-derived cells remain in the BM of the chimeras whether
in non-competitive or competitive environment (Figures 2B and
S2C). Analysis of persistent E4f1D/D cells in peripheral blood
showed that they belonged mostly to B (B220+) lineage (Fig-
ure S2D), consistent with their longer lifespan. Altogether, these
results revealed that the hematopoietic phenotype associated
with E4f1 deletion is cell autonomous.
E4f1 Deficiency Selectively Induces Apoptosis of
Proliferating Progenitors
To investigate the role of E4f1 in HSCs and multipotent progen-
itors, BM isolated from pIpC-treated E4f1+/+ or E4f1F/F mixed
chimeras were analyzed for the expression of stem cell and pro-
genitor markers (Figure 2C). Strikingly, E4f1 deletion resulted in a
near-complete loss of multipotent progenitors (myeloid progen-
itors [MPs] and MPPs) and subsequently in the depletion of all
mature cells (see FACS profiles for frequencies in Figure 2C
and plots for absolute numbers in Figure 2D). Quantification of
more-immature (LT- and ST-HSCs) hematopoietic subsets
showed that, in mixed BM chimeras, where E4f1 mutant
(Ly5.2+) LT-HSCs co-existed with a small proportion of wild-
type (Ly5.1+) HSCs, an increase in relative and absolute numbers
of mutant HSCs is observed. Importantly, frequency and abso-
lute numbers of wild-type (Ly5.1+) LT-HSCs in the same animals
are unaffected (Figures 2C and 2D). Together, these results point
to a dual and opposite role of E4f1 in HSCs and progenitors,
being dispensable in the former and critical in the latter.
Consistently with the massive loss of progenitors, we showed
that E4f1 deficiency induced apoptosis in MP subsets while
sparing HSC-enriched (LSK) population (Figure 2E). Accordingly,
loss of E4f1 enhanced the expression of the pro-apoptotic p53
target gene Puma (Bbc3) and had no significant effect on the
expression of the pro-survival factor Cdkn1a (p21) (Figure 2F).
E4f1 Is Essential for Cell-Cycle Progression and
Genome Integrity
To further evaluate the functional consequences of E4f1 deletion,
we studied the E4f1 phenotype in MEFs. As expected, E4f1(E) The proportion of apoptotic cells in MPs and LSK cells was monitored by ann
(F) Fold change in mRNA transcripts of E4f1 and p53 target genes (cdkn1a and P
E4f1D/+ control cells (means ± SD; n = 3).
See also Figure S2.mutant MEFs rapidly lose their ability to proliferate in vitro, sug-
gesting that somatic cells are also extremely sensitive to E4f1
loss (Figure 3A). Cell-cycle analysis showed that mutant MEFs
accumulated in S phase (Figure 3B). Accordingly, DNA-combing
analysis revealed that E4f1 mutant cells displayed a significant
reduction in replication fork rate compared to control cells (Fig-
ure 3C). These results demonstrated impaired DNA synthesis
and augmented replication stress in E4f1-deleted cells. In line
with these results, we observed by live cell imaging that E4f1
knockout MEFs passing through mitosis consistently formed
chromosome bridges between daughter nuclei (92% in Mscvcre
E4f1D/D MEFs versus 12.5% in Mscvcre E4f1+/+ cells; Figure 3D;
Movies S1 and S2). As chromosome bridges are characteristic
features of persistent DNA damage caused by replication stress
(Chan et al., 2009), we investigated the presence of DNA lesions
in mutant cells. We detected six times more damaged cells in
E4f1mutantMEFs thancontrols as shownbygH2AXstaining (Fig-
ure 3E). We further studied the DNA damage response (DDR) by
monitoring variations in gH2AX levels in response to g-irradiation
(Figure 4F). In contrast to control cells, which demonstrated DDR
initiation and subsequent DNA repair upon this treatment, E4f1-
deficient MEFs displayed constantly high proportions of gH2AX-
positive cells, thereby possibly reflecting dysfunctional DDR
signaling. Altogether, these results point to a critical role for E4f1
in cell-cycle progression and genome integrity.
Akin to hematopoietic cells (Figures 2E and 2F), E4f1-deleted
fibroblasts also showed apoptotic signature (Figure 3G) whereas
no significant senescence features were observed (Figures 3G
and 3H).
E4F1 Determines CHK1 Protein Levels
We then assessed DDR-signaling integrity in E4f1-deficient cells
by studying the basal expression and activation of CHK1 and
CHK2.Whereas CHK2 protein expression levels were similar be-
tween control and E4f1mutant MEFs, we noted a severe reduc-
tion (to near absence) in CHK1 protein levels in E4f1 knockout
cells (Figure 4A). This phenomenon persisted even after chal-
lenging the DDR with the CHK1-activator camptothecin (CPT)
(Flatten et al., 2005). This observation was also confirmed in
lineage-depleted BM cells from wild-type and E4f1D/D mice
(Figure S3A), thus showing the preserved function of E4F1 on
CHK1 protein levels in various cell types. The strict E4f1 depen-
dence for CHK1 expression, in combination with the similar
loss-of-function phenotypes of E4f1 and Chek1 knockout
mice (Liu et al., 2000; Takai et al., 2000; Le Cam et al., 2004),
hinted at an important biological interplay between these two fac-
tors. To further explore this idea, we experimentally introduced a
citrine-E4F1 fusion protein in E4f1 mutant MEFs and monitored
CHK1 abundance. As expected, ectopic citrine-E4F1 expression
restored CHK1 protein expression to basal levels (Figure 4B).
Cellular CHK1 amounts are known to be tightly controlled at
the protein level and negatively impacted by DNA damage
(Zhang et al., 2005). In order to investigate whether increasedexin V/propidium iodide staining (means ± SD; n = 3 mice/genotype).
uma) as assessed by qRT-PCR in primitive E4f1-null FLCs relative to Mscvcre
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Figure 3. E4f1 Is Essential for Cell Cycle Progression and Genome Integrity
(A) Proliferation curve of control and E4f1 mutant MEFs after infection with Mscvcre;YFP vector (means ± SD; n = 3).
(B) Cell-cycle analysis of control and E4f1mutant MEFs using Hoechst labeling. Representative FACS profile (left) and quantification of the percentage of cells in
S phase (right; means ± SD; n = 3).
(C) Distributions of DNA replication fork rates measured by DNA combing in control and E4f1-deleted MEFs are plotted for each of three replicates. Median rates
are indicated by the solid black lines and are listed below the plot, along with the number of nascent DNA tracks measured in each experiment. The p values from
Mann-Whitney U tests are shown for each replicate.
(D) Representative image of mitotic cells in control and in E4f1-null MEFs expressing ectopic H2B-GFP (arrow: chromosome bridge and lagging chromosome;
scale bar represents 20 mm). See also Movies S1 and S2.
(E) Quantification of gH2AX-positive cells in control and E4f1-deleted MEFs by confocal microscopy (means ± SD; n = 3–5).
(F) Quantitative assessment of the number of gH2AX-positive cells in control andmutant MEFs following 5 Gy g-irradiations. Cells were allowed to recover 1 hr or
24 hr at 37C before staining (means ± SD; n = 9–11).
(legend continued on next page)
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Figure 4. E4F1 Interacts with and Protects
CHK1 from Degradation
(A) Representative western blot analysis of DDR
proteins in control and mutant MEFs treated or not
with CPT (n = 3).
(B) Immunoblot analysis of MEFs infected or not
with MscvCitrine-E4f1 that expresses an ectopic
citrine-E4F1 fusion protein (n = 3).
(C) Relative quantification of Chek1 mRNA
expression in E4f1-deficient FLCs and MEFs in
respect to controls (n = 3).
(D) Western blot analysis of E4f1-FLAG-trans-
fected HEK293 cell extracts immunoprecipitated
with either Flag or CHK1 antibodies followed by
revelation of the depicted antigens (n = 3).
(E) Representative western blot analysis of CHK1
protein in cells submitted to cycloheximide assay
(top) and quantification of CHK1 half-life (bottom)
(means ± SD; n = 3).
(F) In vivo ubiquitination assay with or without
ectopic E4f1 expression. Control IgG and endog-
enous CHK1 protein complexes were immuno-
precipitated and blotted with anti-CHK1 and
anti-HA antibodies to reveal ubiquitinated proteins
(left). Input displays equal protein loading and
global ubiquitination profiles (right).
See also Figure S3.DNA damage in E4f1mutant cells was either the cause or conse-
quence of CHK1 loss, we performed time course experiments
monitoring the accumulation of DNA damage by gH2AX staining
and loss of E4F/CHK1 expression. Notably, CHK1 kinetics
strictly followed the decline of E4F1 in mutant cells, 24 hr prior
to the occurrence of detectable DNA damage (Figure S3B).
These results suggest that CHK1 deficiency precedes DNAdam-
age observed in E4f1 mutant cells.
E4F1 Stabilizes Cellular CHK1 Protein
Knowing that E4F1 can function as a transcription repressor
(Fajas et al., 2001), we measured Chek1 mRNA expression in(G) Western blot analysis of activated caspase-3 and p19ARF levels in control and E4f1-deleted MEFs. Cel
G418 for 7 days before protein extraction (n = 2).
(H) Quantification of b-galactosidase-positive cells. Control and mutant MEFs were infected with Mscvcre;neo
(means ± SD; n = 4).
Cell Reports 11, 210–E4f1-deficient FLCs and MEFs. We found
a small but consistent 2-fold reduction in
Chek1mRNA levels, suggesting that tran-
scriptional regulation cannot completely
explain the dramatic reduction of CHK1
protein level observed in E4f1 mutant
cells (Figure 4C). Next, we investigated
whether E4F1 and CHK1 proteins interact
in vivo. Immunoprecipitation experiments
in HEK293 cells, designed to pull down
either ectopically expressed E4F1 or
endogenous CHK1, revealed a physical
interaction between E4F1 and CHK1, but
not with CHK2 (Figures 4D and S3C).Interestingly, ectopically delivered E4F1 also augmented total
cellular CHK1 protein levels, indicating that E4F1 appeared to
be both necessary and sufficient for CHK1 expression (input in
Figure 4D). In order to address the question whether E4F1 regu-
lated CHK1 post-translationally, we evaluated CHK1 protein sta-
bility by cycloheximide-chase analysis (Obrig et al., 1971). A
marked decrease in CHK1 half-life in the absence of E4f1 was
observed in MEFs (8 hr 38 min ± 14 min versus 3 hr 25 min ±
24 min; Figure 4E). Accordingly, in vivo ubiquitination experi-
ments revealed that, although global polyubiquitination was not
affected in cells engineered to overexpress E4F1, the amount
of ubiquitin conjugates was dramatically reduced in CHK1ls were infected with Mscvcre;neo and selected with
and selected with G418 for 7 days before staining
219, April 14, 2015 ª2015 The Authors 215
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Figure 5. Ectopic Chek1 Expression Res-
cues E4f1-Deleted MEFs
(A) Control and E4f1 mutant MEFs were simulta-
neously infected with either Mscvcre;YFP and
MscvGFP, Mscvcre;YFP and MscvChek1;GFP, or
Mscvcre;GFP and MscvCitrine-E4f1. Ratio (mutant/
control) of double-positive cells (GFP+YFP+) were
determined by FACS analysis up to 25 days after
infections (means ± SD; n = 3).
(B) Quantification of gH2AX-positive cells in Mxcre
E4f1D/D MEFs with or without ectopic Chek1
expression. Cells were analyzed by microscopy:
representative images (left; arrowheads point
to DNA-damaged nuclei; scale bar represents
20 mm) and statistical analysis (right; means ± SD;
n = 4–5).
(C) Immunoblot analysis of E4F1, CHK1, and p-p53
(ser15) proteins isolated from control, E4f1mutant,
and Trp53 knockout MEFs expressing, or not,
increasing amount of ectopic Chek1 (n = 3).
(D) Representative FACS analysis of premature
chromatin condensation (PCC) in the indicated
genotypes (right) and quantification (left). Cells
undergoing PCC are pH3+ cells in G1/S phase of
the cell cycle (Huang et al., 2006), in contrast to
pH3+ cells in mitosis (arrow). Results reflect
fold differences in the proportion of cells under-
going PCC relative to wild-type cells (means ± SD;
n = 3–5).
(E) Western blot analysis of E4F1, CHK1, and
p-p53 (ser15) proteins isolated from MEF cells
(with indicated Trp53 genotype) engineered to
express or not either Chek1 or E4f1 (n = 2).
See also Figures S4 and S5.containing protein complexes, strongly suggesting that E4F1
prevents its degradation by the proteasome (Figure 4F). In sum-
mary, these data demonstrate that E4F1 controls cellular CHK1
levels primarily at the protein level.
Forced Expression of CHK1 Completely Rescues the
Defects Seen in E4f1-Deficient MEFs
To validate our assumption of CHK1 regulating genome integrity
downstream of E4F1, we performed a series of CHK1-rescue
experiments in E4f1 mutant MEFs. Importantly, reintroduction
of E4F1 or forced CHK1 expression in E4f1-deleted MEFs
completely restored their proliferation ability whereas expressing
a control GFP led to the progressive loss of E4f1-deficient cells
(Figure 5A). Accordingly, reintroduction of CHK1 substantially
prevents DNA damage occurrence in E4f1 knockout MEFs
(Figure 5B).
Although reintroduction of Chek1 in E4f1-deficient MEFs
restored CHK1 levels in a dose-dependent manner, it only led
to a minor reduction of active DDR signaling, as shown by immu-
noblotting for the DDR-signaling marker Ser15-phosphorylated
p53 (Figure 5C) (Shieh et al., 1997). One characteristic feature216 Cell Reports 11, 210–219, April 14, 2015 ª2015 The Authorsof impaired ATR/CHK1 signaling is a
defect in S phase checkpoint, resulting
in mitotic entry prior to completion of
DNA replication and premature chromatincondensation (PCC) (Nghiem et al., 2001). Therefore, to address
whether E4F1 participates in ATR/CHK1 checkpoint functions,
we analyzed PCC frequency in E4f1 mutant cells heterozygous
for Trp53. Lowering p53 activity deregulates the G1/S phase
transition, thereby increasing the requirement for operational
ATR/CHK1 pathway (Bartek et al., 2004). Clearly, E4f1 disruption
in Trp53+/ background increases occurrence of PCC, which
was completely suppressed by ectopic CHK1 expression
(Figure 5D).
Importantly, we showed that E4f1 mutant MEFs exhibit low
CHK1 protein levels independently of p53 status (Figure 5E,
compare lanes 2 and 6). As p53 is known to downregulate
CHK1 (Gottifredi et al., 2001), our data demonstrate that E4F1
effect on CHK1 stability is dominant and independent of p53.
As expected, reintroduction of E4f1 fully restores CHK1 protein
levels and considerably diminished DDR activation (Figure 5E,
compare lanes 1, 2, and 3). Again, CHK1 ectopic expression re-
duces Ser15-phosphorylated p53 but to a lesser extent than
E4f1-null cells engineered to re-express E4F1 (Figure 5E, lanes
2, 3, and 4), suggesting that other pathways could contribute
to the generation of the observed defect.
CHK1 Ectopic Expression or p53 Abrogation Failed to
Restore the Normal Activity of E4f1-Null Hematopoietic
Cells
We previously showed that proliferative hematopoietic cells
were highly sensitive to loss of E4f1. Accordingly, E4f1 mutant
fetal liver cells (FLCs) rapidly disappeared upon culture (Fig-
ure S4A). Reintroduction of E4f1 in deleted FLCs rescued their
proliferative activity aswell as their clonogenic progenitor capac-
ity (Figures S4A and S4B). However, forced Chek1 expression
failed to rescue E4f1 mutant FLCs (Figures S4A and S4B).
To further evaluate the functional consequence of E4f1 dele-
tion and considering the well-established link between E4F1
and p53 pathway, we performed genetic interaction studies be-
tween these two components. In agreement with the fact that
E4F1 modulates p53 pro-apoptotic functions (Le Cam et al.,
2006), we previously observed a large proportion of apoptotic
cells in E4f1-deficient MPs (Figure 2E) and enhanced expression
of the pro-apoptotic p53 target gene Puma (Bbc3) in deleted
FLCs (Figure 2F). However, concomitant inactivation of E4f1
and Trp53, although delaying the proliferation defect observed
in E4f1-null FLCs, did not rescue cell survival (Figure S4C).
Whereas progenitor activity was partially recovered (Figure S4D),
Trp53 disruption did not restore the in vivo repopulating ability of
E4f1 mutant hematopoietic cells (Figure S4E).
Although supplementation with nucleosides—aiming to
reduce replicative stress—efficiently reduces DNA damages in
E4f1 mutant FLCs, it also could not rescue their proliferation by
itself or along with CHK1 ectopic expression (Figures S5A and
S5B; data not shown). E4f1 disruption has been previously asso-
ciatedwith impairedmitochondrial integrity, leading toROSover-
production (Hatchi et al., 2011a, b; Dai et al., 2014). Notably, anti-
oxidant treatment (addition ofN-acetyl cysteine [NAC]) also failed
to restore proliferation of E4f1-null hematopoietic cells, alone or
in combination with CHK1 overexpression (data not shown).
The fact that single complementation studies cannot rescue
the hematopoietic defect of E4f1mutant cells suggests that mul-
tiple effectors are at play.
DISCUSSION
We demonstrate here that E4f1 expression is essential in the he-
matopoietic system as inactivation leads to apoptosis and sub-
sequent BM failure. This effect is particularly dramatic as mice
die less than 2weeks after gene excision. Usingmixed chimeras,
wewere able to further investigate the impact ofE4f1 inactivation
in hematopoietic sub-populations. Progenitors, which have a
high proliferative potential compared to stem cells, seem to be
particularly affected by E4f1 deletion. Surprisingly, most imma-
ture cells lacking E4f1, including LSK and stem cells, were pre-
served or expanded. This suggests that E4f1 has a distinct role
in progenitors and HSCs, protecting the former from DNA-dam-
age-induced apoptosis. Consistent with differing roles, HSCs
are known to be mostly quiescent, and studies suggest that
they could be more resistant to replicative stress and tolerant
to DNA damage (Beerman et al., 2014; Flach et al., 2014).
The preservation of genome integrity is fundamental for assur-
ing tissue maintenance and preventing tumorigen-
esis. Importantly, cycling cells acquire numerous DNA lesionsunder physiological conditions and thus require functional DDR
pathways to promote DNA repair, cell-cycle arrest, or apoptosis
(Branzei and Foiani, 2008). As perturbing replication often results
in premature mitotic entry and chromosome segregation errors
(Chan and Hickson, 2011), somatic cells lacking E4f1 slow
down replication forks, accumulate in S phase, and are more
prone tomitotic aberrations (anaphase bridges andmicronuclei),
thereby revealing an absolute requirement for E4F1 in S and G2
cell-cycle checkpoint integrity. E4f1 ablation also induces a hy-
per-activated and blunt DDR, consistent with a persistence of
unrepaired damages and checkpoint recovery defects. Taking
further into consideration reports documenting a role for E4F1
during the G1/S phase transition (Fajas et al., 2000; Fenton
et al., 2004), we now identified E4F1 as a central regulator of mul-
tiple cell-cycle checkpoints in proliferating cells.
As for E4F1, CHK1 is a vital protein in proliferating cells best
described as a DNA damage checkpoint regulator during the
S/G2/M phases (Enders, 2008). Strikingly, E4f1 inactivation
is analogous to Chek1 loss of function in response to fork
damages, and lethal knockout embryos share similar features
(Liu et al., 2000; Takai et al., 2000; Le Cam et al., 2004). We
now demonstrate a role for E4F1 in preserving essential CHK1
activity primarily at a post-translational level. Indeed, whereas
E4f1 deletion triggers rapid CHK1 disappearance, E4F1 overex-
pression results in a significant reduction of CHK1 complex
poly-ubiquitination. One could ask whether E4F1 directly mod-
ifies CHK1 protein, protecting it from degradation, or alterna-
tively promotes ubiquitination and subsequent degradation of
a negative regulator of CHK1 (such as Cul4A/DDB1; Leung-
Pineda et al., 2009). Although E4F1 and CHK1 co-immunopre-
cipitate, whether their interaction is direct or indirect and how
E4F1 protects CHK1 from degradation remain to be determined.
Complementary to our results, Rodier et al. (2015) reported that
E4F1 also regulates CHK1 expression at the transcriptional level.
Remarkably, ectopic expression of CHK1 protein in E4f1
mutant MEFs was able to rescue proliferation and prevent accu-
mulation of DNA damage. However, E4f1 mutant cells engi-
neered to re-express CHK1 still exhibit impaired DDR, as
demonstrated by high levels of phosphorylated p53 (ser 15).
This observation strongly suggests that, in addition to CHK1
regulation, other aspects of E4F1 activity might be important
for its role in safeguarding faithful replication of the genome.
Indeed, E4F1 was also documented to regulate mitochondrial
functions (Hatchi et al., 2011a; Rodier et al., 2015), and its disrup-
tion increased autophagy and impaired mitochondrial integrity,
leading to ROS overproduction (Hatchi et al., 2011a, b; Dai
et al., 2014). As elevated ROS and autophagy has been linked
to p53 activation (Liu et al., 2008; Cho et al., 2013), one could
propose that both mitochondrial defects and depletion of
CHK1 contribute to the severe phenotype observed in E4f1
mutant hematopoietic cells. This would explain why
our attempts to rescue in vitro and in vivo hematopoietic cells
by reintroducing CHK1 or inactivating p53 failed.
Overall, the results presented herein document a role for E4F1
in controlling CHK1 activity and further emphasize its ability to
integrate multiple signaling networks into a tight checkpoint con-
trol, ensuring the maintenance of genome integrity in actively
dividing cells.Cell Reports 11, 210–219, April 14, 2015 ª2015 The Authors 217
EXPERIMENTAL PROCEDURES
Experimental Mice
Animals were housed and treated in accordance with institutional and govern-
mental regulations. E4f1 conditional knockout mice were generated by homol-
ogous recombination in ESCs. Trp53 knockout (Jacks et al., 1994) and C57/
bl6-Pep3b mice were purchased from the Jackson Laboratory. Trp53; E4f1
combined strains were maintained on a pure C57/bl6 genetic background.
Cell Culture
PrimaryMEFs and FLCswere isolated from embryonic day 14.5 (E14.5) mouse
embryos and cultured in 10% FBS/DMEM (GIBCO) or FLC expansion medium
(IMDM, 10% FBS, 50 ng/ml Flt3-ligand, 10 ng/ml IL6, 10 ng/ml IL3, 100 ng/ml
SF, and 1 3 105 b-mercaptoethanol), respectively. HEK293 cells were
cultured in 10% FBS/DMEM. Conditions for colony-forming assays of MPs
were reported elsewhere (Thorsteinsdottir et al., 2002). Of note, methylcellu-
lose cultures were performed at early time points, prior to obvious manifesta-
tion of the E4f1 phenotype. MEFs were treated with CPT (2 mM for 2 hr) or with
cycloheximide (100 mg/ml for the indicated incubation period). The following
retroviruses were used for ectopic gene transfer: Mscvcre;YFP, Mscvcre;GFP,
Mscvcre;NEO, Mscvcre;HYGRO, MscvH2B-GFP, MscvGFP, MscvCitrine-E4f1, and
MscvChk1;GFP. The chosen time points of analysis were days 5–9 for MEFs
and days 4 to 5 for FLCs following viral gene transfer, unless indicated other-
wise. More experimental details concerning virus production and primary cell
infection were detailed elsewhere (Kroon et al., 1998).
Flow Cytometry Analysis
For intracellular staining, cells were either fixed with ethanol (BrdU labeling and
PCC) or BD Cytofix/Cytoperm (DNA damage analysis). For cell survival anal-
ysis, live cells were co-stained with Annexin-Alexa350 (Invitrogen) and Pi in
Annexin binding buffer (10 mM HEPES/NaOH [pH 7.4], 14 mM NaCl, and
2.5 mM CaCl2). For cell-cycle experiments, MEFs were incubated 45 min
with 10 mg/ml of Hoechst 33342. FACS surface marker analysis was executed
on a BD LSRII, whereas cell sorting was done on a BD FACS AriaII. Data anal-
ysis was carried out with BD Diva or FlowJo.
Statistical Analysis
Statistical analysis was performed using the Student’s t test unless stated
otherwise in the figure legend. * and ** denote significant (p < 0.05) and highly
significant (p < 0.01) statistical differences, respectively. NS marks no statisti-
cal difference.
Detailed experimental procedures, primer sequences, and used antibodies
are provided in the Supplemental Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and two movies and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2015.03.019.
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